Changes to interests of a significant shareholder

For immediate release

28 April 2017

Alliance Pharma plc

+ 44 (0) 1249 466966

John Dawson, Chief Executive

Andrew Franklin, Chief Financial Officer

Rob Bellhouse, Company Secretary

www.alliancepharma.co.uk

Buchanan

+ 44 (0) 20 7466 5000

Mark Court / Sophie Cowles / Jane Glover

Numis Securities Limited

+ 44 (0) 20 7260 1000

Nominated Adviser: Michael Meade / Freddie Barnfield

Corporate Broking: James Black / Toby Adcock

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

Alliance Pharma plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

√

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to thenotification obligation: iii

Aviva plc & its subsidiaries

4. Full name of shareholder(s)  (if different from 3.):iv

Registered Holder:

Available on request 18,450*

Chase (GA Group) Nominees Limited  22,157,310*

*denotes direct interest

Chase Nominees Limited 733,516

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

26 April 2017

6. Date on which issuer notified:

27 April 2017

7. Threshold(s) that is/are crossed orreached: vi, vii

5% to

(Box 8A & Box 8A&B)

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

Ordinary SharesGB0031030819

24,359,276*

24,359,276*

22,909,276

22,175,760

733,516

4.69%

0.16%

* Includes Right to Recall Loaned Shares (50,000)

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

RIGHT TO RECALL LOANED SHARES

N/A

N/A

50,000*

*Direct Interest

0.01%

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

% of voting rights xix, xx

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

22,959,276

4.86%

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

The voting rights are managed and controlled by Aviva Investors Global Services Limited and Friends Provident International Limited, with the following chain of controlled undertakings:-

Aviva Investors Global Services Limited:

· Aviva plc (Parent Company)

· Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc)

· Aviva Investors Holdings Limited (wholly owned subsidiary of Aviva Group Holdings Limited)

· Aviva Investors Global Services Limited (wholly owned subsidiary of Aviva Investors Holdings Limited)

Friends Provident International Limited:

· Aviva plc (Parent Company)

· Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc)

· Friends Provident International Limited (wholly owned subsidiary of Aviva Group Holdings Limited)

Proxy Voting:

10. Name of the proxy holder:

See Section 4

11. Number of voting rights proxy holder will ceaseto hold:

12. Date on which proxy holder will cease to holdvoting rights:

13. Additional information:

Figures are based on a total number of voting rights of 472,795,052, as per the Company's 'Application for admission' announcement of 31 March 2017.

14. Contact name:

Neil Whittaker, Aviva plc

15. Contact telephone number:

01603 684420